News

March 25, 2024

CureLab Oncology Secures Patent Protection in Canada for Elenagen, Its P62 Plasmid Cancer Therapeutic

This latest patent registration provides a pathway to commercial agreements in Canada with high economic potential for CureLab Oncology; separately, CureLab Oncology has provided exclusive licensing rights to its sister company, CureLab Veterinary, for use with dogs, cats and horses
March 20, 2024

Elenagen, a novel DNA immunotherapy for the deadliest form of ovarian cancer, delays disease progression

Researchers say their ability to create Elenagen was only possible because of their opposition to dominant biotech doctrine
February 29, 2024

Study undermines mechanism-based discovery, says CureLab

February 22, 2024

Elenagen, a novel DNA immunotherapy for ovarian cancer, found to delay disease progression

Progression-free survival of patients treated with chemo+ELENAGEN or chemo only.
December 4, 2023

DNA therapy effective against chemo-resistant ovarian cancer

September 29, 2023

Novel DNA vaccine Elenagen demonstrates promising clinical results

Novel DNA vaccine Elenagen, in combination with a proven chemotherapy, demonstrates promising clinical results against one of the deadliest forms of ovarian cancer
September 29, 2023

CureLab seeks new strategic partners to bring cancer innovation to market

CureLab Veterinary is aiming to commercialize a biologic that can alter the microenvironment of cancerous tumors in pets. S&P Global senior analyst Sian Lazell spoke to the company about its anti-cancer vaccine candidate and future pipeline targets.
July 16, 2023

CureLab Oncology Secures Patent Protection for P62 Plasmid Therapeutic in India

India patent registration opens door to commercial agreements in an enormous market with high economic potential for CureLab Oncology
March 3, 2023

CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne

Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals
November 5, 2022

Biotech Internship Opportunity! FDA/USDA liaison

CureLab Oncology and CureLab Veterinary are looking for interns to work with our FDA/USDA team on regulatory activities
November 11, 2021

OncologyTube interviews Dr. Alex Shneider of CureLab Oncology and Prof. Sergei Krasny

Along with the OncologyTube host Stephanie Comello, Dr. Alex Shneider and Prof. Sergei Krasny discuss results from our clinical studies underway in Belarus. If you have 30 minutes, we invite you to watch the video. We’ve condensed the highlights below.
November 23, 2021

CureLab Oncology Secures Patent Protection in India

Patent registration in India opens door to commercial agreements in an enormous market with rising incidence of cancer
July 16, 2023

CureLab Oncology Secures Patent Protection for P62 Plasmid Therapeutic in India

India patent registration opens door to commercial agreements in an enormous market with high economic potential for CureLab Oncology
September 29, 2023

CureLab seeks new strategic partners to bring cancer innovation to market

CureLab Veterinary is aiming to commercialize a biologic that can alter the microenvironment of cancerous tumors in pets. S&P Global senior analyst Sian Lazell spoke to the company about its anti-cancer vaccine candidate and future pipeline targets.